SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366238191> ?p ?o ?g. }

Showing items 1 to 70 of 70 with 100 items per page.

W4366238191 endingPage "014556132311700" @default.
W4366238191 startingPage "014556132311700" @default.
W4366238191 abstract "Objective To analyze the clinical characteristics of differentiated thyroid cancer (DTC) patients with nasolacrimal duct obstruction (NLDO) after Iodine-131 ( 131 I) therapy and provide guidance for clinical decision-making. Methods Thirty-one DTC patients with NLDO were retrospectively enrolled from the Nuclear Medicine Department of Shanxi Bethune Hospital during follow-up of 131 I therapy between June 2018 and March 2021. Eight hundred and seventy-one thyroid cancer patients during this period without NLDO after 131 I therapy were enrolled as the control group. Clinical characteristics, including sex, age, dose, anti-thyroglobulin antibodies (TGAb), and metastatic lesions, were analyzed by χ 2 test and logistic multifactor regression. Results In the NLDO group and without NLDO group, there were statistically significant differences in gender, age, dose, and whether there was metastasis. Among the NLDO group, the proportion of women, age >55 years old, dose >5.55 GBq, and the presence of metastasis was higher, and the difference was statistically significant; There was no significant difference in the proportion of TGAb positive and negative patients based on 131 I therapy (χ 2 = 0.27, P = .782).Multivariate logistic regression analysis showed that sex (2.59), age (1.45), dose (2.36), and metastatic lesions (1.93) were all statistically significant influential factors of NLDO after iodine therapy. Significant differences were found in the incidence of NLDO between the number of treatment courses (χ 2 = 23.541, P < .001). Prevalence rate of repeat radioiodine therapy (2 times or 3 times and more) is higher than 1 time. Conclusion Women patients over 55 who had metastatic lesions, and received a dose >5.55 GBq, were more likely to have NLDO. When determining therapeutic doses of 131 I, doctors should weigh multiple factors and then give appropriate dosage and suggest that high risk populations be referred for appropriate ophthalmic surgical consultation, for timely diagnosis and therapy." @default.
W4366238191 created "2023-04-20" @default.
W4366238191 creator A5029019255 @default.
W4366238191 creator A5031315906 @default.
W4366238191 date "2023-04-17" @default.
W4366238191 modified "2023-10-01" @default.
W4366238191 title "Clinical characteristics of nasolacrimal duct obstruction after iodine therapy in differentiated thyroid cancer patients" @default.
W4366238191 cites W1979883969 @default.
W4366238191 cites W2312955480 @default.
W4366238191 cites W2335236904 @default.
W4366238191 cites W2609508713 @default.
W4366238191 cites W2806352753 @default.
W4366238191 cites W2911188335 @default.
W4366238191 cites W2944251934 @default.
W4366238191 cites W2953558526 @default.
W4366238191 cites W3121293122 @default.
W4366238191 cites W3195367728 @default.
W4366238191 cites W4200520955 @default.
W4366238191 doi "https://doi.org/10.1177/01455613231170088" @default.
W4366238191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37070248" @default.
W4366238191 hasPublicationYear "2023" @default.
W4366238191 type Work @default.
W4366238191 citedByCount "0" @default.
W4366238191 crossrefType "journal-article" @default.
W4366238191 hasAuthorship W4366238191A5029019255 @default.
W4366238191 hasAuthorship W4366238191A5031315906 @default.
W4366238191 hasBestOaLocation W43662381911 @default.
W4366238191 hasConcept C120665830 @default.
W4366238191 hasConcept C121332964 @default.
W4366238191 hasConcept C121608353 @default.
W4366238191 hasConcept C126322002 @default.
W4366238191 hasConcept C151956035 @default.
W4366238191 hasConcept C167135981 @default.
W4366238191 hasConcept C2778835679 @default.
W4366238191 hasConcept C2779761222 @default.
W4366238191 hasConcept C526584372 @default.
W4366238191 hasConcept C61511704 @default.
W4366238191 hasConcept C71924100 @default.
W4366238191 hasConcept C90924648 @default.
W4366238191 hasConceptScore W4366238191C120665830 @default.
W4366238191 hasConceptScore W4366238191C121332964 @default.
W4366238191 hasConceptScore W4366238191C121608353 @default.
W4366238191 hasConceptScore W4366238191C126322002 @default.
W4366238191 hasConceptScore W4366238191C151956035 @default.
W4366238191 hasConceptScore W4366238191C167135981 @default.
W4366238191 hasConceptScore W4366238191C2778835679 @default.
W4366238191 hasConceptScore W4366238191C2779761222 @default.
W4366238191 hasConceptScore W4366238191C526584372 @default.
W4366238191 hasConceptScore W4366238191C61511704 @default.
W4366238191 hasConceptScore W4366238191C71924100 @default.
W4366238191 hasConceptScore W4366238191C90924648 @default.
W4366238191 hasLocation W43662381911 @default.
W4366238191 hasLocation W43662381912 @default.
W4366238191 hasOpenAccess W4366238191 @default.
W4366238191 hasPrimaryLocation W43662381911 @default.
W4366238191 hasRelatedWork W1970383787 @default.
W4366238191 hasRelatedWork W1986649732 @default.
W4366238191 hasRelatedWork W2275480158 @default.
W4366238191 hasRelatedWork W2325203569 @default.
W4366238191 hasRelatedWork W2352040352 @default.
W4366238191 hasRelatedWork W2374149423 @default.
W4366238191 hasRelatedWork W2996495160 @default.
W4366238191 hasRelatedWork W3209251735 @default.
W4366238191 hasRelatedWork W4281665086 @default.
W4366238191 hasRelatedWork W50598398 @default.
W4366238191 isParatext "false" @default.
W4366238191 isRetracted "false" @default.
W4366238191 workType "article" @default.